Richard Lock, MD

Medical Director, OR Anesthesia

Clinical interests

  • Anesthesiology
  • Cardiac Anesthesiology
  • Hyperbaric Oxygen Therapy

Richard Lock, MD

Medical Director, OR Anesthesia

Biography

My name is Richard Lock; I received my medical degree from Northeastern Ohio Universities, College of Medicine, Rootstown. I completed a fellowship in University of Kentucky, Lexington.

I am board certified by the American Board of Anesthesiology.

Faculty rank

Professor of Anesthesiology, Pediatric Specialty

Education

Degree
Northeastern Ohio Universities, College of Medicine, Rootstown

Residency
University of Kentucky, Lexington

Fellowship
University of Kentucky, Lexington

Certifications or Special training
American Board of Anesthesiology

Anesthesiology

UK Albert B. Chandler Hospital - Pavilion H
800 Rose St.
Lexington KY 40536-0293

Call 859-323-5000

Amenities
ATM, Dining, Gift shop, Information desk, Post office

Directions to UK Albert B. Chandler Hospital - Pavilion H Parking »


UK HealthCare accepts many forms of insurance. See list of insurers »

 
  1. Frolova O, Samudio I, Benito JM, Jacamo R, Kornblau SM, Markovic A, Schober W, Lu H, Qiu YH, Buglio D, McQueen T, Pierce S, Shpall E, Konoplev S, Thomas D, Kantarjian H, Lock R, Andreeff M, Konopleva M. Regulation of HIF-1a signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther. 2012 Aug; 13(10):858-70. PMID: 22785211.
    View in: PubMed
  2. Carol H, Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R, Kolb EA, Billups CA, Geier B, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB. Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013 Apr; 60(4):633-41. PMID: 22753001.
    View in: PubMed
  3. Wallington-Beddoe CT, Don AS, Hewson J, Qiao Q, Papa RA, Lock RB, Bradstock KF, Bendall LJ. Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia. PLoS One. 2012; 7(5):e36429. PMID: 22570713.
    View in: PubMed
  4. Gorlick R, Kolb EA, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA. Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 Dec 15; 59(7):1266-74. PMID: 22315240.
    View in: PubMed
  5. Gorlick R, Maris JM, Houghton PJ, Lock R, Carol H, Kurmasheva RT, Kolb EA, Keir ST, Reynolds CP, Kang MH, Billups CA, Smith MA. Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2012 Sep; 59(3):518-24. PMID: 22102563.
    View in: PubMed
  6. Markovic A, MacKenzie KL, Lock RB. Induction of vascular endothelial growth factor secretion by childhood acute lymphoblastic leukemia cells via the FLT-3 signaling pathway. Mol Cancer Ther. 2012 Jan; 11(1):183-93. PMID: 22084166.
    View in: PubMed
  7. Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJ, Alexander D, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Billups CA, Smith MA. Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 Oct; 59(4):749-52. PMID: 22052829.
    View in: PubMed
  8. Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Morton CL, Wu J, Smith PG, Yu J, Houghton PJ. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 Aug; 59(2):246-53. PMID: 22012946.
    View in: PubMed
  9. Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, Arts J, Bashir T, Janicot M, Kurmasheva RT, Houghton PJ. Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 Aug; 59(2):329-32. PMID: 21922647.
    View in: PubMed
  10. Kolb EA, Gorlick R, Keir ST, Maris JM, Lock R, Carol H, Kurmasheva RT, Reynolds CP, Kang MH, Wu J, Houghton PJ, Smith MA. Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a ?-secretase inhibitor targeting notch signaling. Pediatr Blood Cancer. 2012 May; 58(5):815-8. PMID: 22052798.
    View in: PubMed
  11. Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, Konoplev S, Fang W, Zweidler-McKay PA, Campana D, Borthakur G, Bueso-Ramos C, Shpall E, Thomas DA, Jordan CT, Kantarjian H, Wilson WR, Lock R, Andreeff M, Konopleva M. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One. 2011; 6(8):e23108. PMID: 21853076.
    View in: PubMed
  12. Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Billups CA, Smith MA. Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2012 Apr; 58(4):636-9. PMID: 21681929.
    View in: PubMed
  13. Lock RB, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gorlick R, Kolb EA, Houghton PJ, Smith MA. Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 Jun; 58(6):916-23. PMID: 21584937.
    View in: PubMed
  14. Houghton PJ, Lock R, Carol H, Morton CL, Gorlick R, Anders Kolb E, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups CA, Zhang MX, Madden SL, Teicher BA, Smith MA. Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 Feb; 58(2):200-9. PMID: 21548007.
    View in: PubMed
  15. Kang MH, Reynolds CP, Houghton PJ, Alexander D, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Wozniak A, Smith MA. Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 Jul 15; 59(1):185-8. PMID: 21538821.
    View in: PubMed
  16. Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, Morton CL, Gorlick R, Kolb EA, Keir ST, Wu J, Wozniak AE, Yang Y, Manfredi M, Ecsedy J, Wang J, Neale G, Houghton PJ, Smith MA, Lock RB. Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol. 2011 Nov; 68(5):1291-304. PMID: 21448591.
    View in: PubMed
  17. Reynolds CP, Kang MH, Keir ST, Gorlick R, Kolb EA, Lock R, Maris JM, Carol H, Morton CL, Billups CA, Smith MA, Houghton PJ. Initial testing of lenalidomide by the pediatric preclinical testing program. Pediatr Blood Cancer. 2011 Oct; 57(4):606-11. PMID: 21360651.
    View in: PubMed
  18. Smith MA, Maris JM, Lock R, Kolb EA, Gorlick R, Keir ST, Carol H, Morton CL, Reynolds CP, Kang MH, Houghton PJ. Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2011 Aug; 57(2):268-74. PMID: 21360650.
    View in: PubMed
  19. Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Phelps D, Maris JM, Billups C, Smith MA. Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 Feb; 58(2):191-9. PMID: 21337679.
    View in: PubMed
  20. Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gu Y, Wilson WR, Smith MA. Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2011 Sep; 57(3):443-53. PMID: 21744473.
    View in: PubMed
  21. Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2011 Apr; 56(4):595-603. PMID: 21298745.
    View in: PubMed
  22. Keir ST, Maris JM, Lock R, Kolb EA, Gorlick R, Carol H, Morton CL, Reynolds CP, Kang MH, Watkins A, Houghton PJ, Smith MA. Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010 Dec 1; 55(6):1126-33. PMID: 20672370.
    View in: PubMed
  23. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA. Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2010 Oct; 55(4):668-77. PMID: 20806365.
    View in: PubMed
  24. Lock R. Managing the difficult airway in craniomaxillofacial trauma. Craniomaxillofac Trauma Reconstr. 2010 Sep; 3(3):151-9. PMID: 22110831.
    View in: PubMed
  25. Carol H, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ, Lock RB. Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010 Dec 15; 55(7):1329-37. PMID: 20740623.
    View in: PubMed
  26. Bachmann PS, Piazza RG, Janes ME, Wong NC, Davies C, Mogavero A, Bhadri VA, Szymanska B, Geninson G, Magistroni V, Cazzaniga G, Biondi A, Miranda-Saavedra D, Göttgens B, Saffery R, Craig JM, Marshall GM, Gambacorti-Passerini C, Pimanda JE, Lock RB. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood. 2010 Oct 21; 116(16):3013-22. PMID: 20647567.
    View in: PubMed
  27. Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Wu J, Smith MA, Houghton PJ. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer. 2010 Jul 15; 55(1):26-34. PMID: 20108338.
    View in: PubMed
  28. Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir ST, Watkins A, Smith MA, Lock RB. Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010 May; 54(5):707-15. PMID: 20017204.
    View in: PubMed
  29. Smith MA, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Kang MH, Reynolds CP, Maris JM, Watkins AE, Houghton PJ. Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010 Feb; 54(2):307-10. PMID: 19856388.
    View in: PubMed
  30. Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP, Kang MH, Maris JM, Keir ST, Kolb EA, Wu J, Wozniak AW, Billups CA, Rubinstein L, Smith MA. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther. 2010 Jan; 9(1):101-12. PMID: 20053767.
    View in: PubMed
  31. High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, Khaw SL, Vikstrom IB, Roberts AW, Lock RB. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol. 2010 Mar; 77(3):483-94. PMID: 20038611.
    View in: PubMed
  32. Carol H, Lock R, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009 Dec 15; 53(7):1255-63. PMID: 19554570.
    View in: PubMed
  33. Gorlick R, Kolb EA, Houghton PJ, Morton CL, Phelps D, Schaiquevich P, Stewart C, Keir ST, Lock R, Carol H, Reynolds CP, Maris JM, Wu J, Smith MA. Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009 Oct; 53(4):594-8. PMID: 19554571.
    View in: PubMed
  34. Morton CL, Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA. Initial testing of aplidin by the pediatric pre-clinical testing program. Pediatr Blood Cancer. 2009 Sep; 53(3):509-12. PMID: 19418543.
    View in: PubMed
  35. Keshelava N, Houghton PJ, Morton CL, Lock RB, Carol H, Keir ST, Maris JM, Reynolds CP, Gorlick R, Kolb EA, Wu J, Smith MA. Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009 Sep; 53(3):505-8. PMID: 19418547.
    View in: PubMed
  36. Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, Guthridge MA, Thomas D, Barry EF, Boyd A, Gearing DP, Vairo G, Lopez AF, Dick JE, Lock RB. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009 Jul 2; 5(1):31-42. PMID: 19570512.
    View in: PubMed
  37. Kang MH, Harutyunyan N, Hall CP, Papa RA, Lock RB. Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma. Br J Haematol. 2009 May; 145(3):389-93. PMID: 19298590.
    View in: PubMed
  38. Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds CP, Maris JM, Friedman HS, Dome J, Khoury J, Triche TJ, Seeger RC, Gilbertson R, Khan J, Smith MA, Houghton PJ. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res. 2008 Jul 15; 14(14):4572-83. PMID: 18628472.
    View in: PubMed
  39. Smith MA, Morton CL, Phelps DA, Kolb EA, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Wu J, Houghton PJ. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jul; 51(1):34-41. PMID: 18260120.
    View in: PubMed
  40. Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jul; 51(1):42-8. PMID: 18293383.
    View in: PubMed
  41. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jun; 50(6):1190-7. PMID: 18260118.
    View in: PubMed
  42. Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Wu J, Smith MA. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jun; 50(6):1181-9. PMID: 18085673.
    View in: PubMed
  43. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock RB, Tajbakhsh M, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jun; 50(6):1198-206. PMID: 17914733.
    View in: PubMed
  44. Tajbakhsh M, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Maris JM, Keir ST, Wu J, Reynolds CP, Smith MA, Lock RB. Initial testing of cisplatin by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 May; 50(5):992-1000. PMID: 17554786.
    View in: PubMed
  45. Houghton PJ, Morton CL, Kolb EA, Gorlick R, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Apr; 50(4):799-805. PMID: 17635004.
    View in: PubMed
  46. Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Mar; 50(3):581-7. PMID: 17457854.
    View in: PubMed
  47. Houghton PJ, Morton CL, Kolb EA, Lock R, Carol H, Reynolds CP, Keshelava N, Maris JM, Keir ST, Wu J, Smith MA. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jan; 50(1):37-45. PMID: 17420992.
    View in: PubMed
  48. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Zeidner J, Wu J, Liu T, Billups CA, Khan J, Ansher S, Zhang J, Smith MA. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2007 Dec; 49(7):928-40. PMID: 17066459.
    View in: PubMed
  49. Ong V, Liem NL, Schmid MA, Verrills NM, Papa RA, Marshall GM, Mackenzie KL, Kavallaris M, Lock RB. A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts. J Pharmacol Exp Ther. 2008 Feb; 324(2):434-42. PMID: 17986648.
    View in: PubMed
  50. Bachmann PS, Lock RB. In vivo models of childhood leukemia for preclinical drug testing. Curr Drug Targets. 2007 Jun; 8(6):773-83. PMID: 17584033.
    View in: PubMed
  51. Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned TM, Lock RB, Reynolds CP. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood. 2007 Sep 15; 110(6):2057-66. PMID: 17536015.
    View in: PubMed
  52. Lee EM, Bachmann PS, Lock RB. Xenograft models for the preclinical evaluation of new therapies in acute leukemia. Leuk Lymphoma. 2007 Apr; 48(4):659-68. PMID: 17454623.
    View in: PubMed
  53. Markovic A, MacKenzie KL, Lock RB. FLT-3: a new focus in the understanding of acute leukemia. Int J Biochem Cell Biol. 2005 Jun; 37(6):1168-72. PMID: 15778081.
    View in: PubMed
  54. Liem NL, Papa RA, Milross CG, Schmid MA, Tajbakhsh M, Choi S, Ramirez CD, Rice AM, Haber M, Norris MD, MacKenzie KL, Lock RB. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood. 2004 May 15; 103(10):3905-14. PMID: 14764536.
    View in: PubMed
  55. Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead MG, Israel MA, Lock RB, Maris JM, Merlino G, Patterson W, Reynolds CP, Shannon K, Yu A, Yu J, Smith MA. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res. 2002 Dec; 8(12):3646-57. PMID: 12473573.
    View in: PubMed
  56. Lock RL, Audenaert SM, Richardson CH, Haydon RC. Ventilation by metal suction catheter during tracheal laser surgery performed on a premature infant. Laryngoscope. 1994 Feb; 104(2):226-8. PMID: 8302129.
    View in: PubMed
  57. Audenaert SM, Montgomery CL, Stone B, Akins RE, Lock RL. Retrograde-assisted fiberoptic tracheal intubation in children with difficult airways. Anesth Analg. 1991 Nov; 73(5):660-4. PMID: 1952153.
    View in: PubMed
  58. Lock R, Hessel EA. Probable reversal of protamine reactions by heparin administration. J Cardiothorac Anesth. 1990 Oct; 4(5):604-8. PMID: 2132139.
    View in: PubMed